Portal de investigación
MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Esteve, J
- Konopleva, M
- Martinelli, G
- Ottmann, O
- Rollig, C
- Wei, A
- Vey, N
- Chiu, I
- Monnet, A
- Ott, MG
- Fenaux, P
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Montesinos,P,Esteve,J,Konopleva,M,Martinelli,G,Ottmann,O,Rodriguez,R,Rollig,C et al. MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2019. Chicago-IL. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA:AMER SOC CLINICAL ONCOLOGY. 2019.